Medical Director, Rheumatology, Global Medical Affairs

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases.

Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.

Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized inflammation and disease progression in Multiple Sclerosis (MS). Zenas’ earlier stage programs include ZB021, a clinical-stage, potentially best-in-class, oral, IL-17AA/AF inhibitor; ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor; and ZB014, a preclinical half-life extended anti-CD-19 and FcγRIIb monoclonal antibody.

We are seeking top talent who share our commitment to patients and have a track record of success in acquiring, developing and commercializing products across the globe. Our colleagues have an opportunity to engage in a fast-paced learning environment and experience individual and organizational success as we work towards becoming a global immunology and autoimmune disease leader, while living our values of Transparency, Relationships, Urgency, Excellence, and Innovation – TRUE Innovation!

Zenas Bio Pharma is seeking an experienced and visionary Medical Director, Rheumatology to serve as the Global Medical Affairs medical lead for IgG4-Related Disease (IgG4-RD) and other rheumatologic indications within the portfolio. This individual will provide deep scientific, clinical, and strategic leadership across all aspects of Global Medical Affairs, including evidence generation, scientific communication, launch readiness, and external stakeholder engagement. The role will be central to shaping the global medical strategy for obexelimab, preparing the organization for a launch in IgG4-RD, and supporting additional pipeline programs in autoimmune diseases.

The ideal candidate brings strong rheumatology expertise, clinical credibility in autoimmune diseases, and a proven ability to translate complex science into impactful medical strategy and external engagement.

• Serve as the global medical lead for IgG4-RD and other rheumatologic indications, defining and executing the overall medical strategy in alignment with development, regulatory, and commercial partners.
• Lead development of the Global Medical Affairs Plan, including scientific narrative, medical objectives, and evidence generation priorities.
• Ensure medical excellence across the lifecycle, from Phase 3 readout through launch and post-launch activities.
• Focuses on long-term strategic positioning, cross-portfolio integration, and global alignment across regions.

• Act as the internal subject matter expert in rheumatology and IgG4-RD, providing scientific…